Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4926MR)

This product GTTS-WQ4926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4926MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1306MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ10793MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ12859MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ10016MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ3658MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ6662MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ11032MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ627MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW